Venice Hma LLC
Venice Hma LLC was paid $1.20M by Medicaid between Jan 2018 and Sep 2022, across 101 billing codes. Its largest line is 99283, emergency room visit (moderate) — 12% of everything it billed.
VENICE, FL 34285
Next to other General Acute Care Hospital providers in Florida
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 13,134 | $117K | |
| 2019 | 27,245 | $367K | |
| 2020 | 19,012 | $237K | |
| 2021 | 24,774 | $334K | |
| 2022 | 9,222 | $150K |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 12% | 3,955 | 3,236 | $146K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 11% | 1,809 | 1,409 | $128K |
| 36415 | Collection of venous blood by venipuncture | 9.4% | 6,625 | 4,164 | $113K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.3% | 4,002 | 3,003 | $113K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 6.0% | 1,196 | 1,001 | $72K |
| 96361 | Intravenous infusion, hydration; each additional hour | 5.1% | 1,679 | 1,238 | $61K |
| 70450 | Computed tomography, head or brain; without contrast material | 4.8% | 1,769 | 1,245 | $58K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.6% | 852 | 691 | $56K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.2% | 843 | 739 | $50K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.1% | 2,005 | 1,531 | $50K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.8% | 1,326 | 259 | $46K |
| 80048 | Basic metabolic panel (calcium, ionized) | 3.1% | 6,425 | 4,041 | $38K |
89 more codes
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 2.6% | 1,094 | $32K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.5% | 7,337 | $18K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.4% | 745 | $16K |
| 87077 | 1.1% | 1,212 | $13K | |
| J7030 | Infusion, normal saline solution , 1000 cc | 1.0% | 2,146 | $12K |
| 84484 | <1% | 2,275 | $12K | |
| 87070 | <1% | 851 | $11K | |
| G0378 | Hospital observation service, per hour | <1% | 1,066 | $9K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,548 | $8K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 598 | $8K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,392 | $8K |
| 80076 | <1% | 1,406 | $8K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,422 | $7K |
| 86885 | <1% | 130 | $7K | |
| 87400 | <1% | 295 | $7K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 923 | $6K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 245 | $6K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,028 | $6K |
| 82962 | <1% | 1,136 | $5K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,084 | $5K |
| 81001 | <1% | 3,160 | $5K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,241 | $4K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 272 | $4K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,089 | $4K |
| J2704 | Injection, propofol, 10 mg | <1% | 1,094 | $4K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 508 | $3K |
| 85610 | <1% | 915 | $3K | |
| 80053 | Comprehensive metabolic panel | <1% | 1,090 | $3K |
| 83735 | <1% | 2,201 | $2K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 122 | $2K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 121 | $2K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 403 | $2K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,696 | $2K |
| 84703 | <1% | 269 | $2K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 530 | $2K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,269 | $2K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 376 | $2K |
| 97161 | <1% | 58 | $2K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 197 | $2K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 76 | $1K |
| 87186 | <1% | 792 | $1K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 405 | $1K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 370 | $1K |
| 80061 | Lipid panel | <1% | 108 | $1K |
| 85730 | <1% | 210 | $1K | |
| 86900 | <1% | 156 | $776.65 | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 16 | $771.22 |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 20 | $720.67 |
| 87205 | <1% | 509 | $649.95 | |
| 83605 | <1% | 47 | $641.37 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 46 | $634.59 |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,805 | $578.32 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 58 | $576.27 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 104 | $571.71 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 344 | $565.19 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 40 | $524.75 |
| 83690 | <1% | 1,175 | $484.87 | |
| 91301 | <1% | 87 | $443.72 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 155 | $438.66 |
| 82330 | <1% | 541 | $349.58 | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 14 | $327.03 |
| 82550 | <1% | 161 | $286.15 | |
| 87486 | <1% | 23 | $174.89 | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 48 | $169.86 |
| 87430 | <1% | 127 | $167.44 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 130 | $166.17 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 85 | $162.91 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 224 | $155.27 |
| 83880 | <1% | 43 | $120.40 | |
| 87081 | <1% | 118 | $113.00 | |
| 96376 | <1% | 273 | $109.32 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 749 | $96.24 |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 102 | $81.67 |
| 0012A | <1% | 61 | $37.79 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 282 | $36.00 |
| 87147 | <1% | 12 | $26.32 | |
| 86901 | <1% | 154 | $4.14 | |
| 81025 | <1% | 199 | $1.77 | |
| 84100 | <1% | 113 | $1.48 | |
| 82248 | 0% | 96 | $0.00 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 21 | $0.00 |
| 80143 | 0% | 13 | $0.00 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 0% | 24 | $0.00 |
| 80179 | 0% | 13 | $0.00 | |
| 87040 | 0% | 86 | $0.00 | |
| 85027 | 0% | 56 | $0.00 | |
| 0011A | 0% | 29 | $0.00 | |
| 87581 | 0% | 23 | $0.00 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
| Provider | Location | Paid |
|---|---|---|
| Roswell Hospital Corporation | Roswell, NM | $41.27M |
| Wesley Health System LLC | Hattiesburg, MS | $37.82M |
| Metro Knoxville Hma LLC | Powell, TN | $28.70M |
| Bullhead City Hospital Corporation | Bullhead City, AZ | $28.54M |
| Iom Health System LP | Fort Wayne, IN | $27.50M |
| ST. Joseph Health System, LLC | Fort Wayne, IN | $25.43M |
| Laredo Texas Hospital Company LP | Laredo, TX | $19.46M |
| Oak Hill Hospital Corporation | Oak Hill, WV | $18.77M |
| Cocke County Hma, LLC | Newport, TN | $18.34M |
| Cleveland Tennessee Hospital Company LLC | Cleveland, TN | $16.31M |
| Jefferson County Hma LLC | Jefferson City, TN | $14.31M |
| Northwest Arkansas Hospitals, LLC | Springdale, AR | $11.46M |
| Petersburg Hospital Company LLC | Petersburg, VA | $11.20M |
| Campbell County Hma, LLC | Lafollette, TN | $10.07M |
| Warsaw Health System LLC | Warsaw, IN | $9.95M |
| Longview Medical Center LP | Longview, TX | $9.29M |
| Moberly Hospital Company LLC | Moberly, MO | $8.61M |
| Crestview Hospital Company, LLC | Crestview, FL | $8.15M |
| Kirksville Missouri Hospital Company, LLC | Kirksville, MO | $7.98M |
| Victoria of Texas LP | Victoria, TX | $7.74M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.